Pathogenic Intracellular and Autoimmune Mechanisms in Urticaria and Angioedema
Identifieur interne : 001366 ( Main/Exploration ); précédent : 001365; suivant : 001367Pathogenic Intracellular and Autoimmune Mechanisms in Urticaria and Angioedema
Auteurs : Katherine Altman [États-Unis] ; Christopher Chang [États-Unis]Source :
- Clinical Reviews in Allergy & Immunology [ 1080-0549 ] ; 2013-08-01.
English descriptors
- KwdEn :
Abstract
Abstract: Urticaria and angioedema are common disorders. Chronic urticaria is defined as lasting longer than 6 weeks. Causes of chronic urticaria fall into the following categories: physical, allergic, hereditary, autoimmune, and idiopathic. Basophils and mast cells are the primary effector cells responsible for clinical symptoms and signs. These cells produce and secrete a variety of mediators including histamine, leukotrienes, prostaglandins, cytokines, chemokines, and other pro-inflammatory mediators. This leads to vasodilation, fluid exudation, increased vascular permeability, and accumulation of additional secondary inflammatory cells. Two mechanisms have been investigated as possibly contributing to the pathogenesis of chronic urticaria. One is the development of autoantibodies to FcεRI or IgE on mast cells and basophils. This appears to be responsible for 30–50 % of cases. The other is dysregulation of intracellular signaling pathways involving Syk, SHIP-1, or SHIP-2 in basophils and mast cells. The primary treatment for chronic urticaria is to treat the underlying pathology, if any can be identified. Otherwise, in idiopathic cases, H1 antihistamines, H2 antihistamines, antileukotrienes, and corticosteroids constitute the main pharmacologic treatment modalities. In severe and recalcitrant cases of chronic and autoimmune urticaria, immunosuppressive drugs have been used, most commonly cyclosporin. More recent experimental studies have also suggested that omalizumab, an anti-IgE therapy, may be of benefit. Currently, inhibitors of Syk are also being developed and tested in the laboratory and in animal models. As our understanding of the pathogenesis of idiopathic urticaria increases, development of additional drugs targeting these pathways may provide relief for the significant physical and psychological morbidity experienced by patients with this disorder.
Url:
DOI: 10.1007/s12016-012-8326-y
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001286
- to stream Istex, to step Curation: 001286
- to stream Istex, to step Checkpoint: 000375
- to stream Main, to step Merge: 001367
- to stream Main, to step Curation: 001366
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pathogenic Intracellular and Autoimmune Mechanisms in Urticaria and Angioedema</title><author><name sortKey="Altman, Katherine" sort="Altman, Katherine" uniqKey="Altman K" first="Katherine" last="Altman">Katherine Altman</name></author><author><name sortKey="Chang, Christopher" sort="Chang, Christopher" uniqKey="Chang C" first="Christopher" last="Chang">Christopher Chang</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:898D8EE1E29555B46EC51341C87808E24188692C</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1007/s12016-012-8326-y</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-GHPG6CZ9-J/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001286</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001286</idno><idno type="wicri:Area/Istex/Curation">001286</idno><idno type="wicri:Area/Istex/Checkpoint">000375</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000375</idno><idno type="wicri:doubleKey">1080-0549:2012:Altman K:pathogenic:intracellular:and</idno><idno type="wicri:Area/Main/Merge">001367</idno><idno type="wicri:Area/Main/Curation">001366</idno><idno type="wicri:Area/Main/Exploration">001366</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pathogenic Intracellular and Autoimmune Mechanisms in Urticaria and Angioedema</title><author><name sortKey="Altman, Katherine" sort="Altman, Katherine" uniqKey="Altman K" first="Katherine" last="Altman">Katherine Altman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>1015 Belmont Pl E, 98102, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Chang, Christopher" sort="Chang, Christopher" uniqKey="Chang C" first="Christopher" last="Chang">Christopher Chang</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Allergy, Asthma and Immunology, Thomas Jefferson University, Nemours/AI duPont Hospital for Children, 1600 Rockland Road, 19803, Wilmington, DE</wicri:regionArea><placeName><region type="state">Delaware</region></placeName></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Reviews in Allergy & Immunology</title><title level="j" type="abbrev">Clinic Rev Allerg Immunol</title><idno type="ISSN">1080-0549</idno><idno type="eISSN">1559-0267</idno><imprint><publisher>Springer US; http://www.springer-ny.com</publisher><pubPlace>Boston</pubPlace><date type="published" when="2013-08-01">2013-08-01</date><biblScope unit="volume">45</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="47">47</biblScope><biblScope unit="page" to="62">62</biblScope></imprint><idno type="ISSN">1080-0549</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1080-0549</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angioedema</term><term>Autoimmune</term><term>Basophil</term><term>FcεRI</term><term>Histamine</term><term>IgE</term><term>Leukotriene</term><term>Mast cell</term><term>Omalizumab</term><term>Syk</term><term>Urticaria</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Urticaria and angioedema are common disorders. Chronic urticaria is defined as lasting longer than 6 weeks. Causes of chronic urticaria fall into the following categories: physical, allergic, hereditary, autoimmune, and idiopathic. Basophils and mast cells are the primary effector cells responsible for clinical symptoms and signs. These cells produce and secrete a variety of mediators including histamine, leukotrienes, prostaglandins, cytokines, chemokines, and other pro-inflammatory mediators. This leads to vasodilation, fluid exudation, increased vascular permeability, and accumulation of additional secondary inflammatory cells. Two mechanisms have been investigated as possibly contributing to the pathogenesis of chronic urticaria. One is the development of autoantibodies to FcεRI or IgE on mast cells and basophils. This appears to be responsible for 30–50 % of cases. The other is dysregulation of intracellular signaling pathways involving Syk, SHIP-1, or SHIP-2 in basophils and mast cells. The primary treatment for chronic urticaria is to treat the underlying pathology, if any can be identified. Otherwise, in idiopathic cases, H1 antihistamines, H2 antihistamines, antileukotrienes, and corticosteroids constitute the main pharmacologic treatment modalities. In severe and recalcitrant cases of chronic and autoimmune urticaria, immunosuppressive drugs have been used, most commonly cyclosporin. More recent experimental studies have also suggested that omalizumab, an anti-IgE therapy, may be of benefit. Currently, inhibitors of Syk are also being developed and tested in the laboratory and in animal models. As our understanding of the pathogenesis of idiopathic urticaria increases, development of additional drugs targeting these pathways may provide relief for the significant physical and psychological morbidity experienced by patients with this disorder.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Delaware</li><li>Washington (État)</li></region></list><tree><country name="États-Unis"><region name="Washington (État)"><name sortKey="Altman, Katherine" sort="Altman, Katherine" uniqKey="Altman K" first="Katherine" last="Altman">Katherine Altman</name></region><name sortKey="Chang, Christopher" sort="Chang, Christopher" uniqKey="Chang C" first="Christopher" last="Chang">Christopher Chang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001366 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001366 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:898D8EE1E29555B46EC51341C87808E24188692C
|texte= Pathogenic Intracellular and Autoimmune Mechanisms in Urticaria and Angioedema
}}
| This area was generated with Dilib version V0.6.33. |  |